Cardiovascular Morbidity and Mortality in Chronic Hypoparathyroidism: A Systematic Review and Meta-Analysis.

Calcif Tissue IntOct 5, 2026 (epub)
Clinical ResearchEndocrinologyCardiologyOpen access

Deep Dutta, Kunal Mahajan, Ashima Mittal et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the cardiovascular risks associated with chronic hypoparathyroidism (HypoPT) in adults. Analyzing data from nine cohort studies involving 134,598 participants, the study found that HypoPT was linked to a higher risk of myocardial infarction (HR 1.19, 95% CI 1.06, 1.35).

Key findings

  • HypoPT was associated with a higher risk of myocardial infarction (HR 1.19, 95% CI 1.06, 1.35).
  • The occurrence of heart failure was higher in HypoPT patients (HR 1.46, 95% CI 1.08, 1.96).
  • HypoPT patients had a higher occurrence of arrhythmias (HR 1.45, 95% CI 1.19, 1.76).
  • All-cause mortality was higher in patients with HypoPT (HR 1.40, 95% CI 1.07, 1.84).

Why it matters

Understanding the cardiovascular risks associated with chronic hypoparathyroidism is crucial for clinicians, as it highlights the need for structured cardiovascular assessments in this patient population to potentially improve outcomes.

Source

PubMed · PMID 42832041Free full text on PubMed Central

Published in Calcif Tissue Int. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.